clinicalstudies

Clinical studies at Fraunhofer ITMP

New therapies, medications, and diagnostic procedures are crucial for improving medicine. However, before they can help patients, we must test their efficacy and safety in clinical trials. For this, we need people like you.

We invite you to join us in shaping the future of medicine. Your participation as a trial subject not only gives you the opportunity to benefit from the latest medical developments, but as a trial subject, you are an indispensable part of our team.

Let's work together to develop the next generation of therapies and improve health for our entire community.

 

Why participate?

  • Exclusive access to innovative treatment methods
  • Close medical supervision by experts
  • Contribution to medical progress

At Fraunhofer IMTP, we place the highest priority on the safety and well-being of our study participants. All studies are conducted in accordance with the highest ethical and scientific standards. If you are interested in participating in a study or would like further information, please do not hesitate to contact us. Together, we can shape the medicine of tomorrow.

 

Below you will find all current studies at our institute.

For more information, please click on the respective button.

IMPACT – Inflammation Medicine Patients Active in Research

We want to involve patients more closely in research by getting them to actively participate as experts in their own disease in the planning, implementation and dissemination of innovation projects. This initiative is called “Inflammation Medicine Patients Active in Research” (IMPACT) and is currently being established.

 

1.9.2025

Chronic spontaneous urticaria (Berlin)

This clinical study is investigating the efficacy and safety of a new adrenaline nasal spray for the treatment of acute exacerbations in patients with chronic spontaneous urticaria (CSU).

 

29.9.2025

Phase III study on barzolvolimab for chronic spontaneous urticaria (Berlin)

This international study is investigating the monoclonal antibody barzolvolimab. The aim is to test its efficacy and safety in patients with chronic spontaneous urticaria (CSU) who continue to experience symptoms despite treatment with H1 antihistamines.